Logo

GDRX

GoodRx Holdings, Inc.

GDRX

GoodRx Holdings, Inc. • NASDAQ
$2.81 ▼ -0.71% (-0.02)
Market Cap $953.62 M
52w High $5.81
52w Low $2.61
Dividend Yield 0%
P/E 35.13
Volume 899.68K
Outstanding Shares 339.37M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $196.028M ▼ $167.989M ▲ $1.119M ▼ 0.571% ▼ $0.003 ▼ $36.051M ▼
Q2-2025 $203.07M ▲ $142.281M ▼ $12.843M ▲ 6.324% ▲ $0.036 ▲ $50.035M ▲
Q1-2025 $202.97M ▲ $166.226M ▼ $11.052M ▲ 5.445% ▲ $0.03 ▲ $48.224M ▲
Q4-2024 $198.583M ▲ $168.21M ▲ $6.74M ▼ 3.394% ▼ $0.02 ▼ $41.863M ▲
Q3-2024 $195.251M $163.16M $12.259M 6.279% $0.032 $38.002M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $273.529M ▼ $1.326B ▲ $724.795M ▲ $600.712M ▼
Q2-2025 $281.318M ▼ $1.319B ▲ $675.675M ▲ $643.031M ▼
Q1-2025 $300.981M ▼ $1.295B ▼ $640.924M ▼ $654.347M ▼
Q4-2024 $448.346M ▲ $1.388B ▲ $663.409M ▲ $724.658M ▲
Q3-2024 $423.777M $1.355B $658.412M $696.434M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $1.119M ▼ $0 ▼ $0 ▲ $0 ▲ $0 ▲ $0 ▼
Q2-2025 $12.843M ▲ $49.58M ▲ $-18.315M ▲ $-50.928M ▲ $-19.663M ▲ $49.19M ▲
Q1-2025 $11.052M ▲ $9.413M ▼ $-51.876M ▼ $-104.902M ▼ $-147.365M ▼ $9.271M ▼
Q4-2024 $6.74M ▲ $44.743M ▼ $-16.644M ▼ $-3.53M ▲ $24.569M ▲ $28.099M ▼
Q3-2024 $3.965M $86.862M $-15.859M $-172.129M $-101.126M $86.459M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Other Revenue
Other Revenue
 $10.00M ▲$0 ▼$0 ▲$0 ▲
Prescription Transactions Revenue
Prescription Transactions Revenue
 $290.00M ▲$150.00M ▼$140.00M ▼$130.00M ▼
Subscription Revenue
Subscription Revenue
 $40.00M ▲$20.00M ▼$20.00M ▲$20.00M ▲

Five-Year Company Overview

Income Statement

Income Statement GoodRx’s income statement shows a business that has shifted from early, sizable losses to modest profitability, with revenue growing gradually rather than explosively. The company enjoys very strong gross margins, which means most of each dollar of sales is left after direct costs, but spending on marketing, technology, and overhead keeps overall profit margins thin. Over the last few years, operating results have steadily improved from losses to a small operating profit, and net income has moved from negative to slightly positive. This trend suggests better cost control and operating leverage, but profitability still looks delicate and could swing with any pullback in growth or higher spending needs.

Balance Sheet

Balance Sheet The balance sheet is asset‑light and typical of a software and data platform: relatively few physical assets, a meaningful amount of cash, and a large portion of value tied up in intangibles like brand and technology. Cash levels have declined from earlier years but remain solid enough to provide a cushion, assuming the company keeps generating positive cash flow. Debt is noticeable but not extreme and has been slowly edging down, while shareholder equity has stayed fairly stable. Overall, the balance sheet appears sound but not bulletproof, so maintaining cash discipline remains important, especially in a regulated, fast‑changing healthcare environment.

Cash Flow

Cash Flow Cash flow is a relative strength: GoodRx has consistently produced positive cash from its operations, even in years when accounting profits were negative. After subtracting the company’s modest investment spending, free cash flow has remained positive, indicating the core business generates more cash than it consumes. Capital spending needs are low, which fits an asset‑light, software‑driven model and leaves more room for debt service, marketing, or product investment. The main watchpoint is that the cash engine is solid but not huge, so any major strategic push or regulatory shock would need to be financed carefully.

Competitive Edge

Competitive Edge GoodRx holds a strong position in the U.S. prescription discount market, with high brand recognition among consumers and doctors and a very broad pharmacy network. Its large user base and many pharmacy and PBM relationships create network effects: more users attract more partners and better discounts, which in turn attract even more users. The company also benefits from trust and habit—people tend to return to a service that has saved them money at the pharmacy counter. At the same time, it faces competitive pressure from other discount cards, insurers, PBMs, and digital health platforms, and is exposed to regulatory shifts in drug pricing and pharmacy benefits that could reshape the playing field.

Innovation and R&D

Innovation and R&D Innovation at GoodRx focuses on using data and software to simplify healthcare costs: an AI‑driven pricing engine, a modern cloud‑based tech stack, and tools that quickly produce health content and personalized offers. The company has expanded beyond basic coupons into subscriptions, telehealth, pharma manufacturer programs, and an e‑commerce layer that lets users pay online and pick up in store. Its engineering culture, use of microservices, and selective patents support rapid experimentation and incremental feature launches. The flip side is execution complexity: juggling many new offerings, navigating healthcare regulations, and staying ahead of copycats all raise the bar for consistent, high‑quality innovation.

Summary

Overall, GoodRx looks like a maturing digital healthcare platform: revenue is growing steadily, margins have improved from past losses to slim profits, and cash generation is consistently positive. The balance sheet is reasonably healthy, with manageable debt and a decent cash buffer, but not so strong that the company can afford major missteps. Strategically, GoodRx benefits from strong brand recognition, network effects, and a broad suite of services that go beyond simple prescription discounts, which together form a meaningful competitive moat. The main uncertainties center on regulatory changes, competitive responses from larger healthcare players, and the company’s ability to turn its large audience and innovative product pipeline into durable, higher‑margin growth without overspending.

NEWS

November 17, 2025 · 8:35 AM UTC

GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy®

Read more

November 4, 2025 · 4:05 PM UTC

GoodRx Reports Third Quarter 2025 Results

Read more

October 15, 2025 · 9:00 AM UTC

GoodRx Launches New Hair Loss Subscription for Men to Simplify Access to Affordable Treatment

Read more

October 8, 2025 · 4:05 PM UTC

GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call

Read more

October 6, 2025 · 9:15 AM UTC

GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings

Read more